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background: Endometriosis is still a highly underdiagnosed disease, and the current medical and surgical treatment of endometriosis is
associated with a high recurrence rate. This study investigates the use of derivatives of the human antibody F8, speciﬁc to the alternatively
spliced extra-domain A of ﬁbronectin (Fn), for the imaging and treatment of endometriosis.
methods: Immunohistochemistry and immunoﬂuorescence was used to evaluate antigen expression in endometriotic tissue of human
endometriosis and of a syngeneic mouse model of the disease. The in vivo targeting performance of a ﬂuorescent derivative of the F8 antibody
was assessed by imaging mice with endometriosis using a near-infrared ﬂuorescence imager, 24 h following i.v. injection of the antibody con-
jugate. Furthermore, the mouse model was used for therapy experiments using two recombinant F8-based immunocytokines [F8-interleukin-
10 (IL10) and F8-IL2] or saline for the treatment groups.
results: A very strong vascular expression of splice isoforms of Fn and of tenascin-C was observed in human endometriotic lesions by
immunohistochemistry and immunoﬂuorescence techniques. After i.v. administration, a selective accumulation of the F8 antibody in endo-
metriotic lesions could be observed in a syngeneic mouse model. These targeting data were used as a basis for therapy experiments with a
pro-inﬂammatory (F8-IL2) and an anti-inﬂammatory (F8-IL10) cytokine fusion protein of the F8 antibody. The average lesion size in the F8-
IL10 treatment group was clearly reduced compared with the saline control group and with the F8-IL2 group, for which no therapeutic effects
were observed.
conclusions: The F8 antibody targets endometriotic lesions in vivo in a mouse model of endometriosis and may be used for the non-
invasive imaging of the disease and for the pharmacodelivery of anti-inﬂammatory cytokines, such as IL10.
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Introduction
Endometriosis, a common gynecological disorder characterized by
extrauterine growth of endometrium-like tissue, affects 10% of
women. Common symptoms include dysmenorrhea, abdominal pain
and infertility. Endometriosis is considered to be an estrogen-
dependent disease because and is almost exclusively found in
women between menarche and menopause (Sampson, 1927;
Giudice and Kao, 2004).
Due to unspeciﬁc symptoms of the disease, the only way to
conﬁrm and diagnose peritoneal endometriosis is by laparoscopy.
Attempts to develop reliable non-invasive instruments to detect
endometriosis have mainly remained elusive. Therefore, the
disease is highly underdiagnosed and the time interval between
the appearance of symptoms to diagnosis can be very long
with an average of 11.7 years in the USA (Hadﬁeld et al., 1996),
8 years in the UK (Hadﬁeld et al., 1996) and 6.7 years in
Norway (Husby et al., 2003). Furthermore, the development of
new treatments for endometriosis is challenging since monitoring
of the disease is difﬁcult. A non-invasive diagnostic method is
urgently needed to decrease time to diagnosis and to allow moni-
toring of the disease.
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Treatment of endometriosis has two aims: relief of pain and/or
amelioration of infertility. Conservative surgical removal of endome-
triosis effectively provides pain relief and increases the chances of
pregnancy. However, symptoms recur in upto 75% of women
within 2 years (Giudice and Kao, 2004). Most of the current
medical therapies induce a hypoestrogenic state in patients and are
associated with severe side effects (e.g. reduction in bone mineral
density) (Rice, 2002). The development of new therapeutic options
that do not disturb the normal menstrual cycle and fertility is a
current challenge of endometriosis research (Fedele et al., 2008).
Angiogenesis, the formation of new blood vessels, plays an essential
role in the growth and survival of endometriotic lesions. Similar to
tumor metastases, endometriotic implants require revascularization
to guarantee oxygen and nutrient supply. Correspondingly, a typical
clinical feature of endometriotic lesions is their dense vascular
network. The high vascularization and mitotic activity are observed
particularly in red lesions, suggesting that these lesions are very
active and probably the ﬁrst stage of early implantation of endometrial
glands and stroma (Nisolle et al., 1993; McLaren et al., 1996). The
lower vessel maturation index in red lesion compared with black
lesion supports this observation. It has been shown that angiogenic
cytokines are elevated in the peritoneal ﬂuid, serum and endometrio-
tic tissue of women suffering from the disease (Taylor et al., 2002;
Laschke and Menger, 2007).
Molecules capable of selectively targeting markers of angiogenesis
may offer opportunities for the in vivo imaging of endometriosis and
for the selective delivery of therapeutic agents to endometriotic
lesions.
Our group has extensively studied the use of monoclonal antibodies
speciﬁc to splice isoforms of ﬁbronectin (Fn) and tenascin-C (TnC) for
the targeted delivery of cytokines to the tumor neovasculature. This
pharmacodelivery strategy has been investigated for cancer therapy
applications, leading to the preclinical (Gillies et al., 1998; Nilsson
et al., 2001; Halin et al., 2002; Gafner et al., 2006; Huang et al.,
2007, Kaspar et al., 2007; Marlind et al., 2008; Schliemann et al.,
2009; Pedretti et al., 2010b), and clinical (King et al., 2004; Schrama
et al., 2006; Sauer et al., 2009) investigation of several antibody-
cytokine fusion proteins. The best characterized clinical-stage human
antibodies developed by our group include F8 (speciﬁc to the alterna-
tively spliced extra-domain A (EDA) of Fn (Villa et al., 2008)), L19
(speciﬁc to the alternatively spliced extra-domain B (EDB) of Fn
(Pini et al., 1998)) and F16 (speciﬁc to the alternatively normal adult
tissues (Brack et al., 2006), but are strongly expressed (typically
around vascular structures) in conditions of tissue remodeling (Zardi
et al., 1987; Carnemolla et al., 1989; Chiquet-Ehrismann and
Chiquet, 2003; Neri and Bicknell, 2005). At present, the
pro-inﬂammatory antibody–cytokine fusion proteins L19-interleukin-2
(IL2) (Carnemolla et al., 2002), L19-tumor necrosis factor (TNF)
(Borsi et al., 2003) and F16-IL2 (Marlind et al., 2008) are currently
investigated in multiple Phase II clinical trials in patients with cancer.
Recently, we were able to demonstrate that splice isoforms of Fn
and TnC are present in inﬂammatory conditions such as atherosclero-
sis, rheumatoid arthritis or psoriasis (Matter et al., 2004; Trachsel
et al., 2007a,b; Schwager et al., 2009; Pedretti et al., 2010a). The
pro-inﬂammatory immunocytokine L19-IL2 was found to promote
plaque remodeling and reduce atherosclerotic plaque load in the
Apo E2/2 mouse model of atherosclerosis (Dietrich et al., 2007),
but the same product worsened inﬂammation in the collagen-induced
arthritis (CIA) mouse model of arthritis. By contrast, both L19-IL10
(Trachsel et al., 2007a) and F8-IL10 (Schwager et al., 2009) were
found to be preferentially localized at sites of arthritis and to potently
inhibit disease progression in the CIA model. The promising results of
these studies encouraged us to investigate antibodies speciﬁc to splice
isoforms of Fn and TnC for the imaging of endometriosis and as
vehicles for the pharmacodelivery of IL2 and IL10 to endometriotic
lesions in vivo. In the last years, the potential role of the immune
system in endometriosis pathophysiology has increasingly gained new
attention and a pivotal role of the immune system in the pathogenesis
of endometriosis has been suggested. The peritoneal environment of
women with endometriosis is altered and highly activated. (Giudice
and Kao, 2004). However, it remains unclear whether changes in
inﬂammatory mediators are a cause or a consequence of the
disease. Anti-inﬂammatory (e.g. anti-TNF) (D’Antonio et al., 2000)
as well as immunostimulatory (e.g. IL-12) (Somigliana et al., 1999)
approaches have shown efﬁcacy in mouse models of endometriosis.
Materials and Methods
Immunohistochemical analysis of human and
mouse endometriotic tissue
A deep inﬁltrating inguinal endometriosis sample was obtained according
to standard operating procedures for the analysis of tissue specimens at
the Department of Gynecology of the University Hospital Zurich, during
the early phase of the menstrual cycle from a non-hormonal pretreated
woman. For immunohistochemistry, 10 mm cryostat sections were ﬁxed
in ice-cold acetone and stained for Fn-EDA, Fn-EDB and TnC-A1.
These antibodies do not work on freshly frozen parafﬁn-embedded speci-
mens. Primary antibodies in small immunoprotein (SIP) format (biotiny-
lated) were added onto the sections in a ﬁnal concentration of 2 mg/ml
and detected with streptavidin-alkaline phosphatase complex (Biospa,
Milan, Italy). Fast Red TRSalt (Sigma-Aldrich, St Louis, USA) was used as
the phosphatase substrate. Sections were counterstained with hematoxy-
lin, mounted with Glycergel mounting medium (Dako, Glostrup,
Denmark) and analyzed with an Axiovert S100 TV microscope (Zeiss,
Feldbach, Switzerland).
For immunoﬂuorescence, a double staining for Fn-EDA, Fn-EDB,
TnC-A1 and von Willebrand factor was carried out. The following
primary antibodies were used: biotinylated SIP(F8), SIP(L19), SIP(F16)
and polyclonal rabbit anti-human von Willebrand factor (Dako). For the
detection of the biotinylated SIPs Streptavidin Alexa Fluor 488 (Invitrogen,
Basel, Switzerland) was used. As secondary detection antibody for the
anti-von Willebrand factor antibody, Alexa Fluor 488 goat anti-rabbit (Invi-
trogen) antibody was used. Slides were mounted and analyzed as
described before.
Mouse model of endometriosis
Mouse experiments were performed in agreement with Swiss regulations
and under a project license granted by the Veterina¨ramt des Kantons
Zu¨rich, Switzerland (122/2009). C57BL/6 mice (6–8 week old) were
subjected to ovariectomy 7 days prior to induction of endometriosis.
Mice were anesthesized by isoﬂurane (AttaneTM, Minrad Inc., Buffalo/
NY, USA) in combination with carprofen (Rimadyl, Pﬁzer GmbH, Berlin,
Germany). Carprofen (0.15 mg/mouse) was injected subcutaneously 2 h
before surgery. After ovariectomy, mice were estrogen-treated
(Sigma-Aldrich) (3×/week 4 mg estradiol/mouse in a volume of 100 ml
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arachis oil (Haenseler AG, Herisau, Switzerland) subcutanously injected,
starting 2 days after ovariectomy). Ovariectomy and estrogen treatment
of the mice were done in order to abrogate differences related to the
stage of the estrous cycle. One week after ovariectomy, mice were
divided into two groups: donor mice (33%) and recipient mice (66%).
Donor mice were killed and both uterine horns were removed and sub-
sequently placed in a sterile Petri dish containing sterile saline. Endome-
trium was detached from the uterine muscle and ﬁnely chopped using a
scalpel. Endometrial fragments were suspended in saline and injected
into the peritoneal cavity using a 19 gauge disposable needle (BBraun,
Melsungen, Germany). Mice were killed 4 weeks after transplantation.
Endometriotic lesions were embedded in cryoembedding compound
(Microm, Walldorf, Germany) and stored at 2808C until processed. Sec-
tions (10 mm) were cut and ﬁxed in acetone. Immunohistochemistry and
hematoxylin staining on mouse tissue was conducted as described already,
using biotinylated F8 antibody in the SIP format.
Near-infrared imaging of endometriosis
lesions in mice
Three weeks after transplantation of endometrial tissue, mice were used
for imaging experiments. The selective accumulation of SIP(F8) in the syn-
geneic mouse model of endometriosis was tested by near-infrared imaging
analysis, as described by Birchler et al. (1999a). Brieﬂy, SIP(F8) and
SIP(F16) (as a negative control) were labeled using amine-reactive Alexa
Fluor 750 carboxylic acid (Invitrogen), according to the manufacturer’s
recommendations. Fluorescently, labeled proteins were separated from
unincorporated dye by gel-ﬁltration on disposable PD-10 columns (GE
Healthcare, Glattbrugg, Switzerland). Labeled proteins (300 mg) were
injected into the tail vein of endometriosis mice. Mice were killed and
imaged in a near-infrared mouse imager (Birchler et al., 1999b) 24 h
after injection.
Ex vivo detection of SIP(F8)-Alexa750
After near-infrared imaging, endometriotic lesions were embedded in
cryoembedding compound (Microm) and stored at 2808C until being
processed. Sections (10 mm) were cut and ﬁxed in acetone. SIP(F8)-
Alexa750 was detected using a rabbit anti-human immunoglobulin (Ig)
E antibody (Dako) followed by Alexa Fluor 488 goat anti-rabbit IgG
(Invitrogen). For the detection of blood vessels, a double staining with a
rat anti-CD31 antibody followed by Alexa Fluor 594 donkey anti-rat IgG
(Invitrogen) was carried out.
Therapy experiments with the two
immunocytokines F8-IL2 and F8-IL10
F8-IL2 and F8-IL10 were produced as described before (Schwager et al.,
2009; Frey et al., 2010). The mouse model was set up as described pre-
viously. One day after endometriosis, tissue transplantation mice were
grouped (10 mice/group) and treated intravenously with F8-IL2 (20 mg),
F8-IL10 (200 mg) or saline. The dose of immunocytokine was chosen in
accordance with previous studies in animal models of arthritis (Schwager
et al., 2009) or in cancer (Carnemolla et al., 2002; Frey et al., 2010).
Mice received three injections on Day 1, 4 and 7. Five days after the
last injection mice were killed and analyzed. Lesions were counted and
weighed using an analytical balance (Mettler Toledo AT460 Delta Range,
Greifensee, Switzerland).
Analysis of mouse plasma cytokine levels
Mouse plasma cytokine level analysis was performed at Cytolab (Muelli-
gen, Switzerland). Plasma of four mice of each group (three for the
F8-IL10 group) was analyzed. Furthermore, plasma of four healthy
F8-IL10-treated mice was analyzed. A multiplexed particle-based ﬂow
cytometric cytokine assay was used (Vignali, 2000). MAP Fluorokine cyto-
kine kits were purchased from R&D (Oxon, UK). The procedures closely
followed the manufacturer’s instructions. The analysis was conducted
using a conventional ﬂow cytometer (FC500 MPL, BeckmanCoulter,
Nyon, Switzerland).
Immunoﬂuorescence studies of inﬁltrating
cells
To evaluate the role of effector cell responses in vivo, immunoﬂuorescent
staining of endometriotic sections of therapy mice was carried out using
antibodies against the following antigens: rat anti-mouse F4/80 (anti-
macrophage; Abcam, Cambridge, UK), rat anti-mouse CD45
(anti-leukocyte common antigen; BD Biosciences, San Jose, USA) and
rabbit anti-asialo GM1 (anti-natural killer cell; Wako Pure Chemical Indus-
tries, Tokyo, Japan). Cryosections were ﬁxed by immersion in cold
acetone, and primary antibodies were added and incubated overnight at
48C. For detection, ﬂuorescent Alexa 488- or 594-coupled antibodies
(BD Biosciences) were used. Finally, sections were mounted with Glycer-
gel (Dako). Images were obtained using the individual ﬂuorescent channels
using an Axioskop 2 mot plus (Carl Zeiss).
Statistical analysis
Differences in lesion weight and plasma cytokine levels between thera-
peutic groups were compared using the Mann–Whitney U-test. P-values
, 0.05 were considered signiﬁcant.
Results
Evaluation of antigen expression
by immunohistochemistry
and immunoﬂuorescence
Immunohistochemical and immunoﬂuorescence staining of a human
endometriotic tissue revealed a very strong vascular expression of
the EDA domain of Fn and of the A1 domain of TnC, while EDB
expression was weaker (Fig. 1). Blood vessels were stained in red
using an anti-von Willebrand antibody.
F8 and F16 antibodies exhibited a comparable staining performance
in endometriosis. Since only F8 antibody is able to recognize the
cognate human and murine antigen with identical afﬁnity (Villa et al.,
2008), we continued our preclinical investigations with this antibody.
A syngeneic murine model of endometriosis was developed by
intraperitoneally injecting endometrial tissue of donor mice into
estrogen-treated recipient mice. Three weeks after tissue implan-
tation, mice were killed and endometriosis fragments were analyzed.
Typically, 1–2 lesions were found per animal. Most of the lesions
were embedded in the fatty tissue around the uterine horns or
attached to the peritoneum. Macroscopically, lesions consisted of
white to light yellow nodules, were 2–5 mm in diameter. Hematoxylin
staining revealed the typical glandular and cystic structures of endome-
triosis (Fig. 2A).
Figure 2B represents a three-color immunoﬂuorescence staining of
mouse endometriotic lesions. The antibodies F8 and L19 are shown in
green, blood vessels are stained in red, using an anti-CD31 antibody
and nuclei are stained in blue. The staining pattern of the two anti-
bodies is comparable; however, staining with the antibody F8
appears clearly stronger (Fig. 2B).
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Targeting of F8 in the syngeneic mouse
model of endometriosis
The in vivo targeting performance of F8 was assessed by labeling the
antibody with the near-infrared ﬂuorophore Alexa750 (Neri et al.,
1997; Birchler et al., 1999a,b). The antibody was used in recombinant
SIP format (Borsi et al., 2002), as this format has previously been
shown to display favorable pharmacokinetic properties compared
with the standard IgG format or the smaller single chain variable
fragment (Borsi et al., 2002; Berndorff et al., 2005). Twenty-four
Figure 2 (A) Hematoxylin staining of mouse endometriotic tissue. Mouse lesions show typical glandular (g) and cystic structures (c). (B) Shows
three-color immunoﬂuorescence stainings with F8 or L19 (green), an anti-CD31 antibody that stains endothelial cells (red) and the nuclear stain
4(6-diamidino-2-phenylindole) (blue). A similar stromal staining pattern was observed for F8 and L19. However, the staining with F8 is clearly stronger.
Scale bars ¼ 100 mm.
Figure 1 Immunohistochemical and immunoﬂuorescence staining of human endometriotic tissue. Immunohistochemistry with the SIPs L19, F16 and
F8 was conducted. Furthermore, immunoﬂuorescence double staining with L19, F16 and F8 (green) and von Willebrand factor (red) was carried out.
The anti-von Willebrand factor antibody stains endothelial cells and was used to highlight blood vessels. The antibodies F8 and F16 showed a strong
vascular staining pattern. Scale bars ¼ 100 mm.
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hours after intravenous injection of the ﬂuorescently labeled SIP(F8)
antibody, mice were killed and imaged using an infrared ﬂuorescence
imager (Birchler et al., 1999a). A strong and selective antibody
accumulation in the endometriotic lesions was observed (Fig. 3) and
(Supplementary Fig. 1). By contrast, mice injected with SIP(F16),
which is not cross-reactive on mouse tissue and which was used as
a negative control, did not show any uptake in endometriotic lesions
(Fig. 3A). An ex vivo ﬂuorescence detection of SIP(F8) using secondary
antibody reagents revealed intense ﬂuorescent staining pattern around
vascular structures (Fig. 3B).
Therapy experiment using the two
immunocytokines F8-IL10 and F8-IL2
In order to investigate whether the targeted delivery of
pro-inﬂammatory or anti-inﬂammatory cytokines could provide thera-
peutic beneﬁt in a syngeneic mouse model of endometriosis, the
immunocytokines F8-IL2 (Frey et al., 2010) and F8-IL10 (Schwager
et al., 2009) were used for the treatment of mice with endometriosis.
Therapy was started one day after transplantation of endometriotic
tissue and mice received three injections (Day 1, 4 and 7) of F8-IL2
(20 mg), F8-IL10 (200 mg) or saline. The dose of immunocytokine
used in the study was the one that was found to be effective in
animal models of arthritis (Schwager et al., 2009) or in cancer
studies (Carnemolla et al., 2002; Frey et al., 2010). Mice were killed
5 days after the last injection and assessed for the number and
weight of endometriotic lesions.
In the saline control group, 7 out of 10mice developedendometriosis,
whereas only 3 out of 10 mice developed endometriosis in the F8-IL10
group (Fig. 4A). Furthermore, the average lesion weight was clearly
reduced in the F8-IL10 group compared with the saline control group.
No therapeutic effect could be observed for F8-IL2 (Fig. 4B).
At termination of the therapy experiment a comparative immuno-
ﬂuorescence analysis of inﬁltrating cells from mice treated with
saline or F8-IL10 was conducted (Fig. 4D). However, no signiﬁcant
change in inﬁltration could be observed between the treatment
groups. Furthermore, analysis of plasma cytokines of killed mice did
not show any signiﬁcant differences of IL6, IL2, TNFa levels
between treatment and control groups (Fig. 4C).
Discussion
In this article, we have shown that the EDA domain of Fn is strongly
and selectively expressed around vascular structures in human and
murine endometriotic lesions. Furthermore, we have observed that
the high-afﬁnity human monoclonal antibody F8, speciﬁc to EDA, is
capable of targeting the neovasculature of endometriosis in vivo. Treat-
ment with the anti-inﬂammatory immunocytokine F8-IL10, but not
with the pro-inﬂammatory immunocytokine F8-IL2, resulted in the
establishment of signiﬁcantly smaller endometriotic lesions in a syn-
geneic mouse model of the disease after three intravenous injections.
At present, endometriosis is diagnosed at laparoscopy and there
would be an urgent need for non-invasive reliable detection techniques.
The twomost common imaging tests available for diagnosis are the ultra-
sound and themagnetic resonance imaging. However, normal results on
these tests do not eliminate the possibility of endometriosis. Areas of
endometriosis are often too small to be detected by these tests.
Fludeoxyglucose-poistron emission tomography (PET) method-
ologies have been reported to successfully image endometriomas in
some cases (Jeffry et al., 2004; Derman et al., 2007), but are otherwise
not widely used in the clinical practice. Antibody-labeling with the
clinical-grade PET radionuclide 124I has recently become available as
an easy route for the use of monoclonal antibodies in immuno-PET pro-
cedures (Tijink et al., 2009). 124I has a half-life of 100 h and is ideally
suited to match the pharmacokinetic properties of disease-targeting
antibodies. Indeed, clinical trials for the imaging of cancer patients
with 124I-labeled SIP(L19) and SIP(F16) antibodies are currently
Figure 3 In vivo targeting performance of Alexa750 labeled SIP(F8) antibody in the syngeneic mouse model of endometriosis. (A) Near-infrared
ﬂuorescence imaging. Endometriosis mice were injected with SIP(F8)-Alexa750 or the negative control antibody SIP(F16)-Alexa750. Near-infrared
ﬂuorescence imaging analysis was carried out 24 h after injection. (B) Ex vivo detection of SIP(F8)-Alexa750. To show blood vessels, a double staining
with an anti-CD31 antibody was carried out. SIP(F8) is localized around blood vessels in endometriotic lesions. Scale bars ¼ 100 mm.
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ongoing, while clinical-grade SIP(F8) has recently become available and
will be investigated in immuno-PET studies in the near future.
In principle, near-infrared ﬂuorescence imaging modalities could
also be considered for the molecular imaging of endometriosis,
using ﬂuorescently labeled antibodies (Folli et al., 1994; Neri et al.,
1997; Birchler et al., 1999a,b; Rudin and Weissleder, 2003). Light
transmission through tissue is maximal at around 800 nm wavelength,
with a 10% transmittance through 1 cm of most human tissues (Wan
et al., 1981). For this reason, near-infrared ﬂuorophores such as
Alexa750 derivatives used in this study should be considered. Immu-
nophotodetection procedures have been used for the imaging of
colorectal cancer in mice and in patients (Gutowski et al., 2001).
Furthermore, the clinically approved near-infrared ﬂuorophore indo-
cyanine green has been successfully used for the non-invasive detec-
tion of 10-cm deep breast cancer lesions, with the help of diffuse
optical tomography imaging methodologies (Ntziachristos et al.,
2000). As ﬂuorescence imaging methodologies are often conﬁned to
lesions that are few centimeters deep in abdominal locations, immuno-
PET imaging procedures are likely to be more useful for the detection
of endometriosis in patients. On the other hand, real-time ﬂuor-
escence imaging methodologies could help for disease detection
during surgical procedures.
The therapy outcome in this study indicates a promising biological
activity for the antibody-mediated pharmacodelivery of the anti-
inﬂammatory cytokine IL-10 to sites of endometriosis. In the past,
there have been contrasting views as to whether anti-inﬂammatory or
pro-inﬂammatory treatment regimenswould be preferable for the treat-
ment of patients with endometriosis. On the one hand, it has been
claimed that, the capacity of reﬂuxed endometrial cells to evade
immune-surveillance might be critical for the development of the
disease and a variety of immuno-stimulatory drugs have shown results
in animal models (Somigliana et al., 1999). On the other hand, endome-
triosis represents an inﬂammatory disease, which is believed to progress
with the support of an inﬂammatorymilieu, and anti-inﬂammatory drugs,
such as anti-TNF, have shown encouraging results in animal models of
endometriosis (D’Antonio et al., 2000; D’Hooghe et al., 2006).
Figure 4 Therapy experiment with the two immunocytokines F8-IL10 and F8-IL2. Mice received three treatment injections of F8-IL2, F8-IL10 or
saline (10 mice per group). Five days after the last treatment mice were killed and lesions were counted and weighed. Furthermore, blood was col-
lected from the therapy mice and plasma was analyzed. (A) In the saline control group, 7 mice developed endometriosis, in the F8-IL2 treated group 8
mice and in the F8-IL10 treated group 3 mice developed endometriosis. (B) Analysis of lesion weight. Lesion weight was signiﬁcantly reduced in
F8-IL10-treated mice compared with the saline control group (P ¼ 0.02). Horizontal bars represent the median of each group. 0–1 lesions were
found per mouse. (C) Plasma analysis of cytokines in therapy mice. Plasma was collected 5 days after the last injection, and four samples were analyzed
per group (three samples from the F8-IL10 group). No statistically signiﬁcant change in plasma cytokines could be observed between treated and
untreated mice. (D) Immunoﬂuorescence analysis of inﬁltrating cells. At termination of the therapy experiment, a comparative immunoﬂuorescence
analysis of inﬁltrating cells from mice treated with saline, F8-IL10 or F8-IL2 was conducted. No change in inﬁltration was seen. Scale bars ¼ 100 mm.
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We used 10 mice per treatment group, which led to statistically sig-
niﬁcant conclusions. This number of mice per study group could not
be extended because of the practical complexity in setting up the
mouse model and because of the ethical principle of minimization of
study mice. Scoring of lesions in mice was not blinded, but lesions
were submitted to histological analysis.
In contrast to previous experience of our group in the plasma analy-
sis as a response to immunocytokine treatment (Schwager et al.,
2009), a clear effect of F8-IL10 treatment on plasma levels of
mouse cytokines could not be seen. This may reﬂect an intrinsic differ-
ence in the action of F8-IL10 in mice with endometriosis. Subtle vari-
ations in cytokine levels may require the study of more than four mice
per group, as described in this paper.
Future studies will be needed to investigate whether prolonged
treatment of mice with F8-IL10 or similar agents results in a complete
disappearance of endometriotic lesions. These studies will probably
require the use of fully murine phage-derived antibodies (Sommavilla
et al., 2010) fused to murine IL10, since the repeated administration
of the fully human F8-IL10 immunocytokine is immunogenic in the
mouse. Additionally, combination studies could be performed, to
investigate whether F8-IL10 synergizes with established treatment
modalities, such as GnRH analog, nuclear factor-kB (NF-kB)-inhibitors
and progestins. During treatment with GnRH-a, several inﬂammatory
molecules are down-regulated in the peritoneal ﬂuid of women with
endometriosis (Ferrero et al., 2009) and a decrease in inﬂammatory
and angiogenic responses can be observed (Khan et al., 2010).
Recent studies show that NF-kB-mediated gene transcription pro-
motes inﬂammation, invasion, angiogenesis and cell proliferation of
endometriotic cells. Inhibitors of this pathway could have positive
effects in the treatment of endometriosis and a synergistic effect
with F8-IL10 is possible. Dienogest, a selective progesterone receptor
agonist and a promising therapeutic option, inhibits prostaglandin E2
production (Shimizu et al., 2011). A combination with F8-IL10 may
be beneﬁcial.
Recombinant human IL10 (TenovilTM) has been extensively tested
in patients with inﬂammatory disorders and has exhibited an excellent
tolerability proﬁle at doses up to 25 mg/kg (Huhn et al., 1996; Rosen-
blum et al., 2002). It has been considered an attractive candidate for
therapeutic use based on its potent in vitro immunomodulating activi-
ties and proven effects in several animal models of chronic inﬂam-
mation. Therapeutic efﬁcacy has been observed in Phase I/II clinical
trials in rheumatoid arthritis and psoriasis patients. The clinical devel-
opment of TenovilTM was discontinued because of insufﬁcient efﬁcacy
of the compound in humans. Up to now, IL10 has not been investi-
gated in endometriosis.
F8-IL10 has exhibited an excellent safety proﬁle in rodents and
cynomolgus monkeys and is currently in Phase I clinical development
in combination with methotrexate for the treatment of patients with
rheumatoid arthritis who have failed at least two lines of biological
treatment (Schwager et al., 2009).
In summary, we have shown that the F8 antibody appears to be a
suitable tool for the pharmacodelivery of bioactive moieties to sites
of endometriosis in vivo, which should facilitate imaging and therapy
for the disease. Furthermore, the F8 antibody can now be considered
as a ‘building block’ for the development of additional antibody deriva-
tives and for the implementation of pharmacodelivery strategies in
endometriosis.
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